MeSH D047728 - degenerative myopia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Novartis | Ranibizumab | Lucentis |  | 2007-01-22 | $1,344 M | Q2/22-Q2/25 |
| CHEPLAPHARM Arzneimittel | Verteporfin | Visudyne |  | 2000-07-27 |  |  |
| Samsung Bioepis | Ranibizumab | Byooviz |  | 2021-08-18 |  |  |
| Viatris | Aflibercept | Yesafili |  | 2023-09-15 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
67%2/3
Phase 2
29%2/7
Phase 3
57%4/7
Approved: 2Overall Success rate: 11%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use